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Primary biliary cirrhosis (PBC) is a chronic cholestatic liver condition characterized by the immune-mediated damage of the
intrahepatic bile ducts. Polymorphisms of vitamin D receptor (VDR) are considered to contribute to its pathogenesis however
their incidence varies in diﬀerent populations and their potential association with the course of the disease has not been studied.
InthispaperweinvestigatedtheincidenceandcorrelationofthreeVDRpolymorphisms(BsmI,ApaI orTaqI)withvariousclinical,
biochemical, and serological factors in a homogenous group of 143 Caucasian patients with PBC. Control group comprises 306
DNA samples from umbilical cord blood of healthy newborn children. When compared to controls, we observed a signiﬁcant
dominance of the b allele in the BsmI (OR=1.69 [1.27–2.24]; P = 0.0003) and t allele in the TaqI (OR=0.62 [0.47–0.82],
P = 0.0001) in patients with PBC. Moreover the BsmI and TaqI polymorphisms were associated with the presence of advanced
ﬁbrosis/liver cirrhosis at the diagnosis of PBC. Pairwise linkage disequilibrium (LD) calculations proved that the analyzed SNPs
are within an LD block (100% of LDs were D  > 0.9). Our study showed, for the ﬁrst time, that the analyzed polymorphisms of
VRD may exert an eﬀect on a natural history of PBC.
1.Introduction
Primary biliary cirrhosis (PBC) is a chronic cholestatic liver
condition [1] which may lead to cirrhosis and liver failure
[2, 3]. The presence of highly speciﬁc M2 antimitochondrial
antibodies (AMAs) is a serological hallmark of the disease
[4, 5]. PBC aﬀects mainly women in their 5th and 6th decade
of life and is often associated with other autoimmune con-
ditions. Although etiology of PBC remains to be fully eluci-
dated, genetic factors are known to contribute to its patho-
genesis [6]. Previous studies suggested major histocompat-
ibility complex (MHC) class II polymorphisms as showing
the strongest, mainly protective, association [7]. Four recent
genomewideassociationstudies(GWASs)whichincluded(i)
North American, (ii) Italian (iii) mostly North American,
and (iv) British cohorts, respectively, pointed at a number
of genes potentially involved in the pathogenesis of PBC and
emphasized the role of IL-12 pathway [8–11].
A fat-soluble secosteroid hormone 1,25-dihydroxyvita-
min D3 (1,25(OH)2D3), apart from its central role in cal-
cium and bone metabolism, possesses immunomodulatory
properties and represents an important component of the
immune system homeostasis [12]. Many observations sug-
gest that 1,25(OH)2D3 can inﬂuence the risk of various
autoimmune conditions, such as rheumatoid arthritis, type
1 diabetes, multiple sclerosis, systemic sclerosis, or inﬂam-
matory bowel disease [13–21].
1,25(OH)2D3 exertsthebiologicaleﬀectsthroughitsown
nuclear hormone receptor, the vitamin D receptor (VDR),
which belongs to the family of transacting transcriptional
regulatory factors [22]. VDR is expressed in most tissues and
regulates the expression of as many as 500 target genes in2 Gastroenterology Research and Practice
Table 1: Demographic data of analyzed subjects.
Feature PBC (n = 143) Control group (n = 306)
Age (median; range) 55 (28–90) NA
Gender (M/F) 20/123 NA
Biopsy-conﬁrmed cirrhosis (Y/N) 38/64 NA
AMA (pos/neg) 118/25 NA
ALT (median; range) IU/l (N—3–30) 47 (10–987) NA
AP (median; range ), IU/l (N—40–120) 286 ( 37–1344) NA
GGT (median; range), IU/l (N—3–30) 177 ( 11–1932) NA
Bilirubin (median; range), mg/dl (N—0.2–1.0) 0.9 (0.2–45.0) NA
Albumin (median; range), g/dl (N—3.8–4.4) 4.0 (2.1–5.8) NA
INR (median; range) (N—0.8–1.2) 1.0 (0.8–2.3) NA
Cholesterol (median; range ), mg/dl (N<200) 217 (50–1096) NA
Triglycerides (median; range), mg/dl (N<150) 105 (47–681) NA
the human genome [23]. Recent studies have indicated
several polymorphisms in this large gene. Three of them,
rs1544410 (BsmI), rs7975232 (ApaI) (both in intron 8), and
rs731236 (TaqI; in exon 9), discovered at the 3  end of the
VDR gene, have been analyzed in the past but their eﬀects
on VDR function still remain poorly understood [24–26].
Their relationship with PBC has been suggested in various
populations including the Japanese, Italian, Chinese, Ger-
man, or Hungarian [27–30] but not conﬁrmed with previ-
ously mentioned GWAS. There are also very little available
data about the relationship between these polymorphisms
and clinical, laboratory ﬁndings and susceptibility to liver
cirrhosis in patients with PBC.
In this study we investigated the prevalence of VDR poly-
morphisms in a homogenous cohort of well-characterized
Polish patients with PBC. We also looked at a potential
eﬀect of these polymorphisms on the clinical and laboratory
features in analyzed cohort of patients.
2.MaterialsandMethods
2.1. Patients. One hundred and forty-three patients (20
males, 123 females; median age at diagnosis 55 years, range
28–90 years) were enrolled in this study. All patients met the
criteriaforthediagnosisofPBCrecentlyintroducedbyEASL
Guidelines [31] according to which PBC can be diagnosed if
at least 2 out of the following 3 criteria are fulﬁlled: elevation
of alkaline phosphatase, typical liver histology, and AMA
seropositivity. In 102 (71.3%) of patients the diagnosis of
PBC was conﬁrmed with liver biopsy out of which in 38
(37.2%) histology showed liver cirrhosis. In total, forty-eight
(33.6%) patients had histological/clinical/imaging signs typ-
ical for liver cirrhosis.
Umbilical cord blood samples from 306 healthy newborn
children served as controls. Data of analyzed subjects are
summarized in Table 1. Appropriate informed consent was
obtained from each patient included in the study. The
study protocol was approved by the ethics committee of
Pomeranian Medical University and conforms to the ethical
guidelines of the 1975 Declaration of Helsinki (6th revision,
2008).
2.2.VDRGenotyping. DNAfromperipheralbloodmononu-
clear cells was isolated using the DNeasy Blood & Tissue
Kit (Qiagen). Oligonucleotide primers and TaqMan probes
forVDRpolymorphisms(rs7975232,rs15444410,rs731236)
were designed and synthesized by Applied Biosystems (Assay
ID: C 28977635 19, C 8716062 10, C 2404008 10, resp.).
The ﬂuorescence data were analyzed with allelic discrimina-
tion 7500 Software v.2.0.2.
2.3. Statistical Analysis. Data are shown as means and
standarddeviations.Allstatisticalanalyses(Chi-Square,odds
ratios, conﬁdence intervals) were carried out using StatView
software (Carry, NC, US). The genotype and allelic frequen-
cies were compared between patients and controls using
Fisher’sPLSDtest.Theanalysisofgenotypefrequencywithin
PBC patients in regards to the clinical characteristics was
performed using Fisher’s PLSD test. Linkage disequilibrium
(LD) for rs7975232, rs15444410, and rs731236 for PBC
patients was analyzed with the software Haploview 4.2.
P value < 0.05 was consider considered to be statistically
significant.
3. Results
The following two VDR gene polymorphisms in intron
8 (rs1544410-BsmI; rs7975232-ApaI) and one in exon 9
(rs731236 = TaqI) were analyzed. A signiﬁcant diﬀerence in
genotype frequency between patients with PBC and healthy
controls at the BsmI and the TaqI polymorphisms but not
at the ApaI polymorphism was found. The X2 value and
the prevalence of each genotype are shown in Table 2.W e
found a signiﬁcant association in the frequency of AA (BB)
genotype at the BsmI polymorphism between PBC patients
and controls. AA (BB) genotype was present less frequently
among the patients with PBC (14.0% versus 31.1% in
controls; X2 = 14,89; P = 0.0001). By contrast, at the TaqI
polymorphisms the CC (tt) genotype was represented more
frequently (30.2% versus 12.3% in controls; X2 = 26,07;
P<0,001) and correspondingly, the frequency of TT (TT)
genotype decreased signiﬁcantly in patients with PBC in
comparison to the controls (16.0% versus 33.2% in controls;Gastroenterology Research and Practice 3
Table 2: Distribution of VDR polymorphisms (rs1544410, rs7975232, rs731236) in PBC patients and controls subjects.
Genotype PBC (%) (n = 143) Controls (%) (n = 306) χ2 P
rs1544410 (BsmI)
AA (BB) 20 (14.0%) 95 (31.1%) 14.89 0.0001
GA (bB) 75 (52.4%) 135 (44.1%) 2.49 0.096
GG (bb) 48 (33.6%) 76 (24.8%) 3.71 0.054
rs7975232 (ApaI)
TT (AA) 40 (28%) 75 (24.9%) 0.61 0.43
GT (aA) 80 (56%) 161 (53.5%) 0.43 0.51
GG (aa) 23 (16%) 65 (21.6%) 1.64 0.41
rs731236 (TaqI)
TT (TT) 20 (16%) 100 (33.2%) 17.39 <0.0001
TC (Tt) 77 (53.8%) 140 (54.5%) 2.55 0.26
CC (tt) 46 (30.2%) 37 (12.3%) 26.07 <0.0001
Table 3: Allele association for VDR in patients with PBC and control subjects.
SNP Allele PBC (%) (n = 143) Controls (%) (n = 306) OR (95% CI) P
rs1544410
(BsmI)
G/A
(b/B) 115 (40.2%)/171 (59.8%) 320 (53.2%)/282 (46.8%) 1.69 (1.27–2.24) 0.0003
rs7975232
(ApaI)
G/T
(a/A) 160 (56%)/126 (44%) 311 (51.7%)/291 (48.3%) 0.84 (0.63–1.2) 0.25
rs731236
(TaqI)
T/C
(T/t) 117 (41%)/169 (59%) 364 (60.5%)/238 (39.5%) 0.62 (0.47–0.82) 0.0001
PBC: primary biliary cirrhosis; OR: odds ratio; CI: conﬁdence interval.
X2 = 17,39; P<0,001). We found no diﬀerence at the
polymorphism.
Additionally, the analysis of frequencies of each allele
in the three polymorphic sites demonstrated a signiﬁcant
dominance of the b allele in the BsmI (OR = 1.69 [1.27–
2.24]; P = 0.0003) and t allele in the TaqI (OR = 0.62 [0.47–
0.82];P = 0.0001)inPBCpatientsincomparisontocontrols
(Table 3). Moreover, in patients with PBC, the BsmI and
TaqI polymorphisms were associated with the histological
features of advanced ﬁbrosis deﬁned as stage III and IV on
histology and cirrhosis (stage IV on histology) (Table 4).
Both laboratory markers of the disease severity and AMAs
failed to have any association to analyzed polymorphisms
(Table 4).
Pairwise linkage disequilibrium (LD) calculations con-
ﬁrmed that the analyzed SNPs are within a LD block (100%
of LDs were D  > 0.9) (Figure 1).
4. Discussion
In this study we have analyzed the association between BsmI,
ApaI, and TaqI polymorphisms and the susceptibility for
PBC and severity of the disease in a homogenous group
of Polish patients. We have found that BsmI polymorphism
occurred signiﬁcantly more commonly in patients with PBC
than in controls. These ﬁndings are consistent with the
ones by Vogel et al. [32] and Fan et al. [33], whereas other
studies have found a protective association of the “b”a l l e l e
[27, 34]. Moreover we have shown the high prevalence of
TaqI polymorphism in patients with PBC, what is again in
agreement with the observation by Vogel et al. [32]. In our
study a strong association with PBC was demonstrated with
“t” allele as well as “tt” genotype, but in the study by Vogel
“Tt”genotypewaspredictiveforPBC.Additionally,thestudy
from Tanaka et al. indicated the high prevalence of ApaI in
PBC [27], but our study did not show such association.
One may say that in the era of genomewide association
studies which involve very large cohorts of subjects analyses
aimed at looking at selected polymorphisms in smaller
groups have lost their signiﬁcance. In the context of PBC,
f o u rG W A S sh a v eb e e np e r f o r m e da n di n c l u d e dh o m o g e -
nous groups from Northern American, Italian, mostly
Northern American, and British patients, respectively. The
ﬁrst one suggested the role of polymorphisms of gene encod-
ing IL-12 alpha and beta chains [8]. Further GWASs have
replicated this ﬁnding but also identiﬁed new loci associated
with antigen-presenting cells and CD4 interactions. Most
recent British GWAS identiﬁed 12 new susceptibility loci
[11].
These results clearly show that each new GWAS adds new
susceptibility loci identiﬁed in analyzed populations. Thus
the fact that VDR polymorphisms were not found in already
performed GWAS does not deﬁnitely preclude their role in
the susceptibility to PBC.
In addition, we have looked at the potential correlation
between polymorphisms of VDR gene and clinical and
laboratory ﬁndings in analyzed patients. We noticed that the
polymorphisms of BsmI and TaqI could be associated with4 Gastroenterology Research and Practice
Table 4: Clinical and laboratory data depending on analyzed polymorphisms.
(a)
ApaI (rs7975232)
AA (TT)
(n = 40)
aA (GT)
(n = 80)
aa (GG)
(n = 23)
P
(AA versus Aa)
P
(aa versus Aa)
P
(aa versus AA)
Gender (F/M) 36/4 67/13 20/3 0.4 0.9 0.7
Cirrhosis at Lbx (N/Y) 20/8 34/21 10/9 0.5 0.6 0.2
Advanced ﬁbrosis stage III/IV on
histology (N/Y) 15/11 28/27 8/10 0.6 0.3 0.5
Age of diagnosis (years) 55.0 ±1.75 5 .7 ±1.55 8 ±2.2 0.8 0.4 0.3
AST (IU/mL) 60.0 ±7.98 1 .5 ±14.8 104.5 ±40.4 0.4 0.4 0.2
ALT (IU/mL) 57.0 ±8.08 2 .1 ±14.48 4 .7 ± 21.4 0.2 0.9 0.3
AP (IU/mL) 226.9 ±31.5 288 ±25.9 371.3 ±64.50 . 2 0 . 1 0.02
GGT (IU/mL) 195.7 ±32.0 279.0 ±36.6 280.8 ±44.5 0.1 0.9 0.2
Bilirubin (mg/dL) 4.0 ±1.74 .2 ±0.92 .3 ± 0.9 0.9 0.3 0.4
Albumin (g/dL) 3.6 ±9.73 .8 ±0.13 .9 ± 0.1 0.1 0.9 0.2
INR 1.1 ±0.04 1.1 ±0.03 1.1 ±0.03 0.1 0.1 0.9
Cholesterol (mg/dL) 220.6 ±14.3 241.4 ±18.5 227.3 ±146 0.4 0.7 0.8
TG (mg/dL) 142.4 ±22.9 120.6 ±6.8 125.7 ±18 0.2 0.8 0.5
Sp100 Ab 34/4 62/16 17/5 0.3 0.8 0.3
Gp210 Ab 31/7 67/11 21/1 0.6 0.3 0.2
AMA (Y/N) 31/9 68/12 19/4 0.3 0.7 0.7
(b)
BsmI (rs15444410)
bb (GG)
(n = 48)
bB (GA)
(n = 75)
BB (AA)
(n = 20)
P
(bb versus Bb)
P
( B Bv e r s u sB )
P
(bb versus BB)
Gender (F/M) 40/8 66/9 17/3 0.6 0.7 0.9
Cirrhosis at Lbx (N/Y) 17/22 38/13 9/3 0.004 0.9 0.1
Advanced ﬁbrosis stage III/IV on
histology (N/Y) 15/23 30/20 6/5 0.1 0.7 0.5
Age of diagnosis (years) 57.0 ±1.65 4 .4 ±1.45 9 .8 ±3.1 0.2 0.1 0.4
AST (IU/mL) 110.0 ±29.26 3 .0 ±5.66 3 .1 ± 13.3 0.05 0.9 0.2
ALT (IU/mL) 91.9 ±22.36 8 .6 ±9.06 2 .7 ± 13.5 0.2 0.8 0.3
AP (IU/mL) 321.8 ±35.3 283.2 ±29.3 195.3 ±26.4 0.4 0.2 0.06
GGT (IU/mL) 312.0 ±48.3 240.1 ±29.6 170.4 ±35.6 0.2 0.3 0.7
Bilirubin (mg/dL) 3.3 ±1.04 .4 ±1.12 .8 ± 2.0 0.5 0.5 0.8
Albumin (g/dL) 3.9 ±0.18 .4 ±4.63 .9 ± 0.2 0.4 0.6 0.9
INR 1.1 ±0.02 1.1 ±0.03 1.1 ± 0.1 0.2 0.4 0.9
Cholesterol (mg/dL) 233.6 ±18.6 239.5 ±17.1 206.8 ±21.2 0.8 0.4 0.5
TG (mg/dL) 126.2 ±9.9 133.9 ±13.3 103 ±10.4 0.6 0.2 0.4
Sp100 Ab 35/12 63/10 15/3 0.1 0.7 0.5
Gp210 Ab 41/6 62/11 16/2 0.8 0.9 0.9
AMA (Y/N) 40/8 63/12 15/5 >0.9 0.3 0.5
(c)
TaqI (rs731236)
TT (TT)
(n = 20)
Tt (TC)
(n = 77)
Tt (CC)
(n = 46)
P
(TT versus
tT)
P
(tt versus tT)
P
(tt versus TT)
Gender (F/M) 37/9 69/8 17/3 0.2 0.7 0.7Gastroenterology Research and Practice 5
(c) Continued.
TaqI (rs731236)
TT (TT)
(n = 20)
Tt (TC)
(n = 77)
Tt (CC)
(n = 46)
P
(TT versus
tT)
P
(tt versus tT)
P
(tt versus TT)
Cirrhosis at Lbx (N/Y) 15/9 40/13 9/3 0.3 >0.9 0.7
Advanced ﬁbrosis Stage III/IV on
histology (N/Y) 13/23 32/20 6/5 0.03 0.7 0.3
Age of diagnosis (years) 57 ±1.65 4 ±1.46 0 ±3 0.2 0.1 0.4
AST (IU/mL) 114.3 ±30.46 1 .6 ±5.56 3 .4 ±13.2 0.03 0.9 0.2
ALT (IU/mL) 94.2 ±23.26 7 .8 ±8.86 3 .3 ±13.4 0.2 0.9 0.3
AP (IU/mL) 322.7 ±.36.4 283.6 ±28.7 195.5 ±26.4 0.4 0.2 0.06
GGT (IU/mL) 309.3 ±50.2 243.1 ±29.2 173.4 ±35.1 0.2 0.4 0.09
Bilirubin (mg/dL) 3.9 ±1.14 .1 ±1.02 .8 ±1.9 0.9 0.6 0.6
Albumin (g/dL) 3.8 ±0.18 .3 ±4.53 .9 ±0.2 0.4 0.6 0.9
INR 1.1 ±0.03 1.1 ±0.03 1.1 ±0.1 0.6 0.5 0.7
Cholesterol (mg/dL) 234.7 ±19.6 239.2 ±16.5 204.4 ±21.2 0.8 0.3 0.4
TG (mg/dL) 125.5 ±10.3 133.9 ±12.8 103.8 ±10.8 0.6 0.2 0.4
Sp100 Ab 34/11 64/11 15/3 0.2 0.9 0.7
Gp210 Ab 39/6 64/11 16/2 0.9 0.9 0.9
AMA (Y/N) 40/6 62/15 16/4 0.5 >0.9 0.5
Lbx: liver biopsy; AspAT: aspartate aminotransferase; AlAT: alanine aminotransferase; AP: alkaline phosphatase; GGT: gamma-glutamyl transferase; INR:
international normalized ratio; TG: triglycerides, AMA: antimitochondrial antibodies.
Promotor Exon Exon  2 Exon 9
TaqI
(rs731236)
ApaI
(rs7975232)
BsmI
(rs1544410)
12 3
5 3
1e
Vitamin D receptor (VDR/ chr. 12q13.11 )
0.94
P<0.01 ×10−14
0.92
P<0.01 ×10−14
0.95
P<0.01 ×10−14
Figure 1: Pairwise linkage disequilibrium (LD) pattern of the VDR gene SNPs: Rs15444410, rs7975232, rs731236. The location of each
examined SNP along the chromosome is indicated. Each square plots the level of D’ values between the pair of SNPs.
the susceptibility to liver cirrhosis or advanced ﬁbrosis in
these subjects which is a new ﬁnding. However we found
no signiﬁcant correlations between the cholestasis or the
prevalence of autoantibodies and the presence of analyzed
polymorphisms.
Little is known on how the genotype variety of VDR gene
is linked to clinical course of the disease as previous studies
focused mostly on the prevalences of each polymorphisms in
PBC. It is possible that the allelic variety of BsmI and TaqI
polymorphisms somehow predisposes to more severe liver6 Gastroenterology Research and Practice
injury, independently of the biochemical measurements of
cholestasis or autoimmune process. Other studies suggested
thatVDRpolymorphismscancontributetothedevelopment
of osteoporosis in patients with PBC [35]; however on the
grounds of recent evidence, it is more likely that the choles-
tasis itself is the main factor of hepatic osteodystrophy, and
the indentiﬁed polymorphisms play little or no role in the
pathogenesis of this complication in patients with PBC [36].
Interpretation of the signiﬁcance of polymorphisms in
the VDR gene is hindered by the fact that the functional
eﬀects of allelic variations are poorly understood. Indeed,
VDR polymorphisms are considered to be associated with
an increased risk of several autoimmune diseases, but
so far no correlation has been identiﬁed with functional
phenotypes [27]. It can be explained by the fact that the
TaqI polymorphismresultsinasilentmutationinexon9and
the location of the BsmI and ApaI is intronic, thus probably
these polymorphisms are anonymous [37]. Thus it could be
speculated that BsmI and TaqI are genetic markers of the
presence of other, so far unknown functional sequence vari-
ations nearby in the VDR gene which is in linkage disequi-
librium with identiﬁed alleles [27, 32]. Because the linkage
disequilibrium can vary through populations, in diﬀerent
studies the same polymorphisms can be associated with
inverse relationships to disease susceptibility. Additionally,
the pathogenesis of PBC is for sure multifactorial, inﬂuenced
by several environmental and genetic interactions and the
analysis of one or few genetic factors in diﬀerent populations
may be insuﬃcient to explain observed variables.
The immunomodulatory properties of 1,25(OH)2D3
may be one of possible explanations on how VDR poly-
morphisms can contribute to the pathogenesis of PBC.
1,25(OH)2D3 activates monocytes and macrophages and
acts as a positive regulator of the development of Th2
cells and production of anti-inﬂammatory interleukin (IL)-4
and transforming growth factor β [38, 39]. Moreover, VDR
agonists inhibit lymphocyte Th1 cell proliferation and pro-
duction of a number of proinﬂammatory cytokines (i.e., IL-
1,IL-2,IL-6,IL-12,interferonγ,tumornecrosisfactorα,and
β)[ 40–42]. PBC is considered a Th1-mediated liver disease
[43]; therefore, reduced activity of 1,25(OH)2D3-dependent
signaling pathways caused by the VDR polymorphisms
might skew the immune response to the Th1 pathway,
contributing to the development of PBC [27].
Other mechanism, in which VDR polymorphisms can be
involved in the pathogenesis of PBC, is a role of VDR as a
receptor for a lithocholic acid (LCA) as well as an endocrine
receptorforvitaminDsignaling.LCAisasecondarybileacid
produced by intestinal bacteria from primary bile acids that
may escape reabsorption in the intestine and can accumulate
to high levels in the enterohepatic circulation of some
subjects [44]. LCA is hepatotoxic and has been considered
to be involved in the pathogenesis of cholesterol gallstone
disease and colon cancer [45, 46]. VDR is expressed in
biliary epithelial cells [47] ,w h e r ei ti sc o n s i d e r e dt oa c ta s
a sensor for toxic secondary bile acids and to induce their
elimination through a xenobiotic metabolism pathway. It
can be speculated that VDR polymorphisms may somehow
disturb the eﬀective biliary elimination of LCA contributing
in this way to the biliary damage and development of PBC.
The investigation of VDR-regulated LCA metabolism will be
helpful in understanding the potential role of the secondary
bile acids in PBC pathogenesis.
In summary, in this present study we have shown the
association of BsmI and TaqI polymorphisms of VDR with
the susceptibility to PBC in a cohort of Polish patients. Also
we have shown that these patients have an increased risk of
liver cirrhosis and advanced ﬁbrosis which is a novel ﬁnding
of this study. Further studies focused not only on the iden-
tiﬁcation of risk polymorphisms involved in development
of PBC but also on the mechanism in which they lead to
development and the course of the disease are warranted.
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